The Immuno-oncology Drugs theme has 5 member stock(s) today, with an average return of -1.9%. The leading stock is 셀리드 (-1.3%, trading value 514,467,363).
Third-generation immuno-oncology drugs that activate immune cells within the body, gaining attention as a centerpiece of global bio tech exports due to fewer side effects and higher cure rates compared to traditional chemotherapy.
| Stock | Price | Return | Trading Value |
|---|---|---|---|
| 셀리드 | 2,320 | -1.3% | 514,467,363 |
| 한올바이오파마 | 49,300 | -1.6% | 10,278,552,800 |
| 에이비엘바이오 | 64,900 | -1.8% | 9,800,382,300 |
| 지아이이노베이션 | 8,370 | -2.0% | 2,647,108,145 |
| 압타바이오 | 6,400 | -3.0% | 103,958,205 |
This page's data is for reference only and is not investment advice. Actual market data may differ.